NASDAQ:APVO - Aptevo Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$4.98 +0.04 (+0.81 %)
(As of 06/18/2018 04:00 PM ET)
Previous Close$4.94
Today's Range$4.87 - $5.10
52-Week Range$1.15 - $6.35
Volume83,238 shs
Average Volume178,322 shs
Market Capitalization$111.57 million
P/E Ratio-3.24
Dividend YieldN/A
Beta0.65

About Aptevo Therapeutics (NASDAQ:APVO)

Aptevo Therapeutics logoAptevo Therapeutics Inc., a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn. The company's marketed products also comprise HepaGam B used for the prevention of hepatitis-B recurrence following liver transplantation in HBsAg-positive liver transplant patients, and for the treatment following exposure to hepatitis-B; and VARIZIG for use in treating following exposure to varicella zoster virus, which causes chickenpox in high-risk individuals. Its investigational stage product candidates include MOR209/ES414, a bispecific immunotherapeutic protein that is in Phase I clinical trial for metastatic castration-resistant prostate cancer; ES210, a bispecific protein therapeutic that is in pre-clinical development stage for inflammatory bowel diseases; otlertuzumab, a monospecific protein therapeutic that is in Phase II clinical trial for chronic lymphocytic leukemia; ROR1, a bispecific immunotherapeutic protein that is in preclinical development; APVO436, a bispecific protein therapeutic, which is in pre-clinical development; and other therapeutic protein product candidates for cancer. The company was incorporated in 2016 and is based in Seattle, Washington.

Receive APVO News and Ratings via Email

Sign-up to receive the latest news and ratings for APVO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:APVO
CUSIPN/A
Phone206-838-0500

Debt

Debt-to-Equity Ratio0.20
Current Ratio4.47
Quick Ratio4.39

Price-To-Earnings

Trailing P/E Ratio-3.24
Forward P/E Ratio-1.89
P/E GrowthN/A

Sales & Book Value

Annual Sales$14.66 million
Price / Sales7.67
Cash FlowN/A
Price / CashN/A
Book Value$3.83 per share
Price / Book1.30

Profitability

EPS (Most Recent Fiscal Year)($1.53)
Net Income$6.97 million
Net Margins5.40%
Return on Equity-47.64%
Return on Assets-31.99%

Miscellaneous

Employees121
Outstanding Shares22,590,000

Aptevo Therapeutics (NASDAQ:APVO) Frequently Asked Questions

What is Aptevo Therapeutics' stock symbol?

Aptevo Therapeutics trades on the NASDAQ under the ticker symbol "APVO."

How were Aptevo Therapeutics' earnings last quarter?

Aptevo Therapeutics Inc (NASDAQ:APVO) announced its quarterly earnings results on Thursday, May, 10th. The biotechnology company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.56) by $0.07. The biotechnology company had revenue of $4.07 million for the quarter, compared to analysts' expectations of $3.37 million. Aptevo Therapeutics had a net margin of 5.40% and a negative return on equity of 47.64%. View Aptevo Therapeutics' Earnings History.

When is Aptevo Therapeutics' next earnings date?

Aptevo Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, August, 9th 2018. View Earnings Estimates for Aptevo Therapeutics.

What price target have analysts set for APVO?

2 brokers have issued 1-year target prices for Aptevo Therapeutics' stock. Their forecasts range from $9.00 to $12.00. On average, they expect Aptevo Therapeutics' stock price to reach $10.50 in the next year. View Analyst Ratings for Aptevo Therapeutics.

Who are some of Aptevo Therapeutics' key competitors?

Who are Aptevo Therapeutics' key executives?

Aptevo Therapeutics' management team includes the folowing people:
  • Mr. Marvin L. White, Pres, CEO & Director (Age 56)
  • Mr. Jeffrey G. Lamothe, Sr. VP & CFO (Age 52)
  • Dr. Scott C. Stromatt, Sr. VP of Clinical Devel. & Medical Affairs and Chief Medical Officer (Age 60)
  • Mr. Randy Joe Maddux, Sr. VP of Operations & Chief Manufacturing Officer (Age 57)
  • Dr. Jane A. Gross, Sr. VP & Chief Scientific Officer (Age 61)

Has Aptevo Therapeutics been receiving favorable news coverage?

Headlines about APVO stock have been trending somewhat positive recently, Accern Sentiment reports. The research group ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aptevo Therapeutics earned a news sentiment score of 0.08 on Accern's scale. They also assigned news coverage about the biotechnology company an impact score of 47.03 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are Aptevo Therapeutics' major shareholders?

Aptevo Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Dimensional Fund Advisors LP (5.44%), JPMorgan Chase & Co. (1.13%), Victory Capital Management Inc. (0.96%), Alambic Investment Management L.P. (0.88%), Park West Asset Management LLC (0.82%) and Spark Investment Management LLC (0.58%). Company insiders that own Aptevo Therapeutics stock include Marvin L White and Randy Joe Maddux. View Institutional Ownership Trends for Aptevo Therapeutics.

Which institutional investors are selling Aptevo Therapeutics stock?

APVO stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC. View Insider Buying and Selling for Aptevo Therapeutics.

Which institutional investors are buying Aptevo Therapeutics stock?

APVO stock was acquired by a variety of institutional investors in the last quarter, including Alambic Investment Management L.P., JPMorgan Chase & Co., Park West Asset Management LLC, Dimensional Fund Advisors LP, Spark Investment Management LLC, Citadel Advisors LLC and Victory Capital Management Inc.. View Insider Buying and Selling for Aptevo Therapeutics.

How do I buy shares of Aptevo Therapeutics?

Shares of APVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aptevo Therapeutics' stock price today?

One share of APVO stock can currently be purchased for approximately $4.98.

How big of a company is Aptevo Therapeutics?

Aptevo Therapeutics has a market capitalization of $111.57 million and generates $14.66 million in revenue each year. The biotechnology company earns $6.97 million in net income (profit) each year or ($1.53) on an earnings per share basis. Aptevo Therapeutics employs 121 workers across the globe.

How can I contact Aptevo Therapeutics?

Aptevo Therapeutics' mailing address is 2401 4TH AVENUE SUITE 1050, SEATTLE WA, 98121. The biotechnology company can be reached via phone at 206-838-0500 or via email at [email protected]


MarketBeat Community Rating for Aptevo Therapeutics (APVO)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  73 (Vote Outperform)
Underperform Votes:  86 (Vote Underperform)
Total Votes:  159
MarketBeat's community ratings are surveys of what our community members think about Aptevo Therapeutics and other stocks. Vote "Outperform" if you believe APVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.